Role of Subthalamic Nucleus in Speech and Movement Among People With Parkinson's Disease as Revealed by Intraoperative Recordings and Deep Brain Stimulation

Status: Recruiting
Location: See location...
Study Type: Observational

Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) have unpredictable and varied speech outcomes after this treatment. Our research will prospectively document speech performance before, during and 6- and 12-months after STN-DBS in 80 surgically treated patients and compared with 40 non-surgical controls with Parkinson's disease. This study will provide unique insights into the role of STN in speech production, document speech outcome in a comprehensive fashion, identify factors that predict functional communication ability 12 months after STN-DBS, and test the feasibility of low frequency DBS in reversing DBS-induced speech declines in order to optimize treatment strategies for those living with Parkinson's disease.

Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 84
Healthy Volunteers: No

• For inclusion in this study, participants must

• have a confirmed diagnosis of idiopathic Parkinson's disease and no atypical Parkinsonism features

• experience significant motor fluctuations

• currently taking and responsive to dopaminergic medications (e.g. Levodopa)

• use English as their primary language

• lack significant cognitive impairment and be able to consent to participate

United States
University of Iowa Hospitals and Clinics
Iowa City
Contact Information
Jeremy Greenlee, MD
Annie Rohl, MS
Time Frame
Start Date: October 15, 2020
Estimated Completion Date: July 2025
Target number of participants: 120
The DBS-STN group will consist of individuals with Parkinson's disease who have already elected to undergo deep brain stimulation surgery.
The control group will consist of individuals with Parkinson's disease who are not undergoing deep brain stimulation placement. No interventions will be completed with the control group.
Collaborators: National Institutes of Health (NIH), Northwestern University, University of Pittsburgh, University at Buffalo, National Institute on Deafness and Other Communication Disorders (NIDCD)
Leads: Jeremy Greenlee

This content was sourced from

Similar Clinical Trials